CereGate unveils breakthrough: Scientific publication demonstrates that spinal cord implants can be repurposed to serve as computer-brain-interfaces.
8 January 2024
CereGate is glad to announce the publication of our groundbreaking paper in “Brain Stimulation”. Brain Stimulation is a premier peer-reviewed journal in the field of neuromodulation.
In this paper we demonstrate that Spinal Cord Stimulator (SCS) implants can be repurposed to serve as computer-brain-interfaces (CBI). This innovative CBI is capable of transmitting rhythmic cues, Morse code, and
essential postural information. Individuals exhibited quick adaptability, efficiently using the CBI across various tasks. The widespread availability of SCS implants positions it as a strong contender among other CBI platforms. This proof-of-concept not only signals a significant development in neurotechnology but also lays the groundwork for potential future clinical applications, marking a step forward in the integration of spinal cord implants and cognitive interfaces. Our approach opens up entirely new possibilities, turning existing implants into powerful computer-brain interfaces - connecting machine and mind with the technology of today.
The study was performed in close collaboration with the team of Dr. Loránd Erōss from the National Institute of Mental Health, Neurology, and Neurosurgery in Budapest, Hungary. The full text is open access and can be obtained here . A demonstration video of the spinal computer-brain interface can be viewed here.
CereGate's CEO Dr. Bálint Várkuti Shares Insights on Cutting-Edge Neural Interfaces in Latest Podcast Appearance
20 March 2024
We are thrilled to share some exciting news with you all! Our CEO, Dr. Bálint Várkuti, recently had the pleasure of being a guest on the Neural Implants Podcast. The episode, now available for streaming, offers valuable insights into the world of cutting-edge neural interfaces, as well as a deep dive into the innovations and future of CereGate. They shed light on the challenges faced in the neural interface industry and shared some of the success stories and breakthroughs that our incredible team has achieved. Furthermore, Dr. Bálint Várkuti gave a sneak peek into the future developments CereGate is working on, including accessibility and scalability for a wider range of applications. We invite you to listen to this engaging and thought-provoking conversation by following the link below:
Partners
Truventuro
TruVenturo is one of the leading company builders in Europe, investing at the forefront of digitalization and life sciences. TruVenturo’s current portfolio includes over 20 companies, among them several industry leaders and hidden champions.
468
468 Capital is a venture capital investor focusing on European tech companies. Founded in 2020 by Alexander Kudlich, Florian Leibert and Ludwig Ensthaler, 468 Capital invests in pre-seed and early growth phases of a company. 468 Capital offers portfolio companies not only financial resources, but also strategic support as well as access to US growth funds.
Re.Mind
re.Mind Capital is a mental & neurological health venture fund, founded by Christian Angermayer, Max de Vere and Jan Hardorp. Angermayer is best-known for his pioneering investments into psychedelics-based treatments for mental health, and is a co-founder of atai Life Sciences. re.Mind’s first fund manages USD 150m, making it the largest early-stage fund dedicated to the brain. With around 20 portfolio companies to date, they invest into companies in neurotech/BCI, biotech, digital tools, and new treatment modalities.
High-Tech Gründerfonds
HTGF is a venture capital investor for innovative technologies and business models.
Healcapital
Heal Capital is a European venture capital fund backing mission-driven founders with capital and HealthTech-specific expertise, accelerating market access.
CARMA FUND
CARMA FUND I is an early-stage investment fund for advancing the translation of Life Science and Healthcare assets.
